AOD-9604

AOD 9604 is a modified version of the hGH fragment 176-191 peptide, distinguished by the presence of a di-sulfide bridge. Originally designed as a lipolytic (fat burning) compound, AOD 9604 has exhibited promising outcomes in various areas of medical research. Studies have explored its potential benefits in addressing conditions such as heart disease, osteoarthritis with a focus on cartilage repair, and metabolic syndrome. Notably, AOD 9604 has demonstrated its ability to stimulate lipolysis, the process of breaking down or destroying fat, while concurrently inhibiting lipogenesis in animal models.

Developed as an anti-obesity drug due to its favorable lipolytic properties, AOD 9604 is valued for its specificity in targeting fat burning without significantly affecting insulin levels or insulin-like growth factor 1 (IGF-1) levels. Unlike some compounds associated with metabolic effects, AOD 9604 does not pose a risk of promoting glucose intolerance. Additionally, its structural similarity to HGH has been advantageous, as it does not tend to elicit an immune system response, eliminating concerns about the formation of antibodies against the peptide. These characteristics contribute to the appeal of AOD 9604 in the realm of medical research and potential therapeutic applications.